SCHEMBL13464636

SCHEMBL13464636

Cc1cc(N=O)ccc1-n1c(C)cc(C=C2SC(=O)N(c3ccc(Cl)cc3)C2=O)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TCF4 P15884 1/20 0.52
▸ CTNNB1 P35222 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ S1PR4 O95977 5/20 0.47
▸ S1PR1 P21453 4/20 0.47
▸ S1PR5 Q9H228 3/20 0.47
▸ NR1H4 Q96RI1 2/20 0.47
▸ KMT2A Q03164 6/20 0.45
▸ MEN1 O00255 5/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ NR2F2 P24468 1/20 0.43
▸ PTPN1 P18031 1/20 0.42
▸ APOBEC3A P31941 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ MYC P01106 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ MAPT P10636 5/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12009723 0.92 TCF4 (0.53) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009734 0.90 TCF4 (0.63) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009021 0.88 TCF4 (0.52) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009024 0.84 NR1H4 (0.64) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009030 0.83 KMT2A (0.52) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009730 0.82 TCF4 (0.56) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL18545653 0.81 NR1H4 (0.60) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009025 0.81 NR1H4 (0.60) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009028 0.81 S1PR4 (0.58) TCF4CTNNB1HDAC6S1PR4S1PR1
SCHEMBL12009023 0.80 TCF4 (0.57) TCF4CTNNB1HDAC6S1PR4S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 TCF4 22/4885CTNNB1 1/4885HDAC6 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback